Cell-based therapies in pulmonary hypertension: who, what, and when?
about
Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension.Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis.
P2860
Cell-based therapies in pulmonary hypertension: who, what, and when?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cell-based therapies in pulmonary hypertension: who, what, and when?
@en
Cell-based therapies in pulmonary hypertension: who, what, and when?
@nl
type
label
Cell-based therapies in pulmonary hypertension: who, what, and when?
@en
Cell-based therapies in pulmonary hypertension: who, what, and when?
@nl
prefLabel
Cell-based therapies in pulmonary hypertension: who, what, and when?
@en
Cell-based therapies in pulmonary hypertension: who, what, and when?
@nl
P2093
P2860
P1476
Cell-based therapies in pulmonary hypertension: who, what, and when?
@en
P2093
Ellen Burnham
Kurt R Stenmark
Susan Majka
P2860
P304
P356
10.1152/AJPLUNG.00118.2011
P577
2011-04-22T00:00:00Z